betaxolol has been researched along with Blood Pressure, High in 63 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data on office blood pressure (BP) and pulse rate as well as information on adverse effects were collected from 148 patients with mild and moderate hypertension during 12 week treatment with long acting lipophilic selective beta-adrenoreceptor blocker betaxolol (20 mg/day)." | 9.11 | [Confirmation of safety and therapeutic effect of betaxolol in the treatment of mild and moderate hypertension in general medical practice]. ( Ageev, FT; Belousov, IuB; Egorova, NA; Ivleva, AIu; Oleĭnikov, VE; Sidorenko, BA, 2005) |
| "The study of hypotensive efficacy of high-cardioselective beta-blocker betaxolol, its effects on lipid and carbohydrate metabolism, menopausal syndrome in females with mild and moderate arterial hypertension." | 9.09 | [Betaxolol treatment of hypertension in postmenopausal women]. ( Britov, AN; Bystrova, MM; Eliseeva, NA; Gorbunov, VM; Lebedev, AV; Metel'skaia, VA, 1999) |
| "The objective of this study was to assess the medium-term effects of betaxolol, a long-acting, lipid-soluble, cardioselective, beta-adrenergic antagonist, alone and in combination with nitrendipine on blood pressure (BP) and metabolism of lipid, lipoprotein and apolipoprotein in patients with mild to moderate hypertension." | 9.08 | Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension. ( Arakawa, K; Jimi, S; Liu, K; Okamoto, T; Saku, K; Takeda, Y; Zhang, B, 1996) |
| "The efficacy and safety of daily 20 mg betaxolol monotherapy was investigated in mild-moderate essential hypertension in a four week long, open label, single blind trial (with a placebo run-in)." | 9.08 | [Effect of betaxolol on blood pressure and heart rate in mild to moderate hypertension]. ( Keltai, M; Matos, L; Ofner, P, 1997) |
| "The open, long-term antihypertensive, hemodynamic and metabolic effects of betaxolol in combination with furosemide and minoxidil were investigated on 30 male patients with moderate to severe essential hypertension." | 9.07 | Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension. ( Berlin, L; Chrysant, C; Chrysant, SG; Sadeghi, M, 1991) |
| "This study determined the dose-response relationship among three doses of betaxolol compared with placebo in patients with mild-to-moderate hypertension." | 9.07 | Dose-dependent effects of betaxolol in hypertension: a double-blind, multicenter study. ( Goyle, KK; Herman, TS; Hogan, LB; Rofman, BA; Ruoff, GE; Williams, RL, 1992) |
| "Sixteen patients with mild to moderate hypertension were randomized to receive either atenolol 100 mg a day (group A: 2 females, 6 males, mean age 42." | 9.06 | [Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension]. ( Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Herpin, D, 1987) |
| "A double-blind, multicenter study compared the safety and efficacy of oral betaxolol 10 to 40 mg once daily (n = 68) with propranolol 40 to 160 mg twice daily (n = 73) in the treatment of mild to moderate essential hypertension." | 9.06 | Comparison of betaxolol, a new beta 1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension. ( Cangiano, J; Davidov, ME; Glazer, N; Wollam, G; Zager, PG, 1988) |
| "Association of polymorphism of b1-adrenoreceptors gene and cytochrome 2D6 gene with efficacy of b-adrenoblocker betaxolol was studied in 81 patients with I and II degree arterial hypertension." | 7.74 | [Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension]. ( Brovkin, AV; Kochkina, MS; Mankhaeva, BB; Minushkina, LO; Nikitin, AG; Nosikov, VV; Savel'eva, EG; Sidorenko, BA; Zateĭshchikov, DA; Zateĭshchikova, AA, 2008) |
| "To report a case of deterioration of asthma associated with continuous use of oral betaxolol, a beta1-selective beta-blocking agent." | 7.72 | Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on beta-receptor occupancy. ( Miki, A; Ohtani, H; Sawada, Y; Tanaka, Y, 2003) |
| "To study efficacy and tolerance of cardioselective beta-adrenoblocker lokren (betaxolol) in elderly patients with mild and moderate hypertension." | 7.70 | [Pharmacodynamic effects of lokren (betaxolol) in 3 month treatment of blood hypertension in elderly patients]. ( Guseĭnzade, M; Komissarenko, IA; Lazebnik, LB; Shakurova, MIu, 1998) |
| " In 10 patients with essential hypertension, we investigated the influence of betaxolol, a selective beta 1-adrenergic blocking agent, on renal function and on plasma levels of ANP during exercise, volume depletion and volume expansion." | 7.68 | Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. ( Grabensee, B; Heering, P; Hollenbeck, M; Kutkuhn, B; Plum, J, 1991) |
| "Twenty two pregnant women with mild to moderate hypertension were treated with betaxolol (10-40 mg/day), a cardioselective beta adrenoceptor blocking agent." | 7.68 | Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy. ( Bianchetti, G; Boutroy, JL; Boutroy, MJ; Morselli, PL; Pépin, L; Zipfel, A, 1990) |
| " The effect of an eight-week treatment with betaxolol, a selective beta-blocker, was studied in patients with moderate hypertension and normal renal function." | 7.67 | Influence of treatment by betaxolol on the renal response to postural changes in moderate hypertension. ( Aissa, AH; Labeeuw, M; Madonna, O; Pozet, N; Zech, P, 1988) |
| "Betaxolol is a cardioselective beta-blocker, which has a bioavailability of 90% and a T 1/2 of 20 h." | 6.65 | Comparison of two doses of betaxolol and placebo in hypertension: a randomized, double-blind cross-over trial. ( Palminteri, R; Salonen, JT, 1982) |
| "Betaxolol is a relatively cardioselective beta-adrenoceptor blocking drug, with no partial agonist (intrinsic sympathomimetic) activity and weak membrane-stabilising (local anaesthetic) activity." | 6.37 | Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. ( Beresford, R; Heel, RC, 1986) |
| "Betaxolol is a selective antagonist of beta(1)-adrenergic receptors." | 5.34 | Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. ( Brovkin, AN; Manchaeva, BB; Minushkina, LO; Nikitin, AG; Nosikov, VV; Savel'eva, EG; Sidorenko, BA; Zateyshchikov, DA; Zateyshchikova, AA, 2007) |
| "The aim of this single-blind study was to compare the efficacy of betaxolol treatment (20 mg/day) on 24-h blood pressure profiles in working men and women with mild hypertension (grade 1 acc." | 5.11 | Working women are better responders to beta-blocker monotherapy of mild hypertension than men. ( Dabrowski, R; Kowalik, I; Szwed, H; Wozniak, J, 2004) |
| "Data on office blood pressure (BP) and pulse rate as well as information on adverse effects were collected from 148 patients with mild and moderate hypertension during 12 week treatment with long acting lipophilic selective beta-adrenoreceptor blocker betaxolol (20 mg/day)." | 5.11 | [Confirmation of safety and therapeutic effect of betaxolol in the treatment of mild and moderate hypertension in general medical practice]. ( Ageev, FT; Belousov, IuB; Egorova, NA; Ivleva, AIu; Oleĭnikov, VE; Sidorenko, BA, 2005) |
| "The study of hypotensive efficacy of high-cardioselective beta-blocker betaxolol, its effects on lipid and carbohydrate metabolism, menopausal syndrome in females with mild and moderate arterial hypertension." | 5.09 | [Betaxolol treatment of hypertension in postmenopausal women]. ( Britov, AN; Bystrova, MM; Eliseeva, NA; Gorbunov, VM; Lebedev, AV; Metel'skaia, VA, 1999) |
| "The objective of this study was to assess the medium-term effects of betaxolol, a long-acting, lipid-soluble, cardioselective, beta-adrenergic antagonist, alone and in combination with nitrendipine on blood pressure (BP) and metabolism of lipid, lipoprotein and apolipoprotein in patients with mild to moderate hypertension." | 5.08 | Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension. ( Arakawa, K; Jimi, S; Liu, K; Okamoto, T; Saku, K; Takeda, Y; Zhang, B, 1996) |
| " To assess the frequency of ischemia-type ST-segment depressions in these patients and the influence of heart rate (HR) and blood pressure (BP) as major determinants of myocardial oxygen demand and to test the effects of beta-blocker therapy (10-20 mg betaxolol/day for 4 weeks) on these variables, simultaneous 24-h Holter and 24-h ambulatory BP monitoring was performed in 19 patients with hypertension (age, 43-71 years; nine women, 10 men) without CAD (stenosis < 50% in angiography)." | 5.08 | Spontaneous changes of heart rate, blood pressure, and ischemia-type ST-segment depressions in patients with hypertension without significant coronary artery disease: beneficial effects of beta-blockade. ( Christ, M; Frey, A; Klauss, V; Krüger, T; Rauen, P; Theisen, K; Wehling, M, 1996) |
| "The efficacy and safety of daily 20 mg betaxolol monotherapy was investigated in mild-moderate essential hypertension in a four week long, open label, single blind trial (with a placebo run-in)." | 5.08 | [Effect of betaxolol on blood pressure and heart rate in mild to moderate hypertension]. ( Keltai, M; Matos, L; Ofner, P, 1997) |
| "The open, long-term antihypertensive, hemodynamic and metabolic effects of betaxolol in combination with furosemide and minoxidil were investigated on 30 male patients with moderate to severe essential hypertension." | 5.07 | Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension. ( Berlin, L; Chrysant, C; Chrysant, SG; Sadeghi, M, 1991) |
| "The antihypertensive and metabolic effects of betaxolol (20 mg/day) were monitored in 40 patients (17 male), aged 54 +/- 2 yr (mean +/- SEM), with moderate essential hypertension." | 5.07 | Betaxolol in obese hypertensive patients. Long-term effects on blood pressure and serum lipids. ( van Brummelen, P; van Os, JS; Woittiez, AJ, 1992) |
| "This study determined the dose-response relationship among three doses of betaxolol compared with placebo in patients with mild-to-moderate hypertension." | 5.07 | Dose-dependent effects of betaxolol in hypertension: a double-blind, multicenter study. ( Goyle, KK; Herman, TS; Hogan, LB; Rofman, BA; Ruoff, GE; Williams, RL, 1992) |
| "In this multicenter, double-blind, parallel study, the antihypertensive effects of betaxolol (20 mg once daily) and/or chlorthalidone (25 mg once daily) were analyzed in 186 patients with essential hypertension." | 5.06 | Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination. ( Burris, JF; Davidov, ME; Ginsberg, D; Jain, AK; Jenkins, P; Mroczek, WJ; Rofman, B; Rosenbaum, R; Ryan, JR, 1989) |
| "Sixteen patients with mild to moderate hypertension were randomized to receive either atenolol 100 mg a day (group A: 2 females, 6 males, mean age 42." | 5.06 | [Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension]. ( Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Herpin, D, 1987) |
| "A double-blind, multicenter study compared the safety and efficacy of oral betaxolol 10 to 40 mg once daily (n = 68) with propranolol 40 to 160 mg twice daily (n = 73) in the treatment of mild to moderate essential hypertension." | 5.06 | Comparison of betaxolol, a new beta 1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension. ( Cangiano, J; Davidov, ME; Glazer, N; Wollam, G; Zager, PG, 1988) |
| " This study examined the age-related effects of betaxolol on HR, muscle sympathetic nerve activity (MSNA), blood pressure (BP) and sympathovagal balance in untreated males with hypertension and tachycardia." | 3.88 | Age-dependent sympathetic neural responses to ß ( Chrostowska, M; Hering, D; Kucharska, W; Narkiewicz, K, 2018) |
| "Association of polymorphism of b1-adrenoreceptors gene and cytochrome 2D6 gene with efficacy of b-adrenoblocker betaxolol was studied in 81 patients with I and II degree arterial hypertension." | 3.74 | [Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension]. ( Brovkin, AV; Kochkina, MS; Mankhaeva, BB; Minushkina, LO; Nikitin, AG; Nosikov, VV; Savel'eva, EG; Sidorenko, BA; Zateĭshchikov, DA; Zateĭshchikova, AA, 2008) |
| "To report a case of deterioration of asthma associated with continuous use of oral betaxolol, a beta1-selective beta-blocking agent." | 3.72 | Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on beta-receptor occupancy. ( Miki, A; Ohtani, H; Sawada, Y; Tanaka, Y, 2003) |
| "To study efficacy and tolerance of cardioselective beta-adrenoblocker lokren (betaxolol) in elderly patients with mild and moderate hypertension." | 3.70 | [Pharmacodynamic effects of lokren (betaxolol) in 3 month treatment of blood hypertension in elderly patients]. ( Guseĭnzade, M; Komissarenko, IA; Lazebnik, LB; Shakurova, MIu, 1998) |
| "Twenty two pregnant women with mild to moderate hypertension were treated with betaxolol (10-40 mg/day), a cardioselective beta adrenoceptor blocking agent." | 3.68 | Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy. ( Bianchetti, G; Boutroy, JL; Boutroy, MJ; Morselli, PL; Pépin, L; Zipfel, A, 1990) |
| " In 10 patients with essential hypertension, we investigated the influence of betaxolol, a selective beta 1-adrenergic blocking agent, on renal function and on plasma levels of ANP during exercise, volume depletion and volume expansion." | 3.68 | Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. ( Grabensee, B; Heering, P; Hollenbeck, M; Kutkuhn, B; Plum, J, 1991) |
| " To test this statement, 12 patients with mild to moderate hypertension performed a submaximal exercise test during treatment with placebo and after 3 and 24 months of monotherapy with betaxolol, 20 to 40 mg daily." | 3.67 | Exercise during therapeutic beta-blockade: a two-year study in hypertensive patients. ( Frisk-Holmberg, M; Ström, G, 1986) |
| " The effect of an eight-week treatment with betaxolol, a selective beta-blocker, was studied in patients with moderate hypertension and normal renal function." | 3.67 | Influence of treatment by betaxolol on the renal response to postural changes in moderate hypertension. ( Aissa, AH; Labeeuw, M; Madonna, O; Pozet, N; Zech, P, 1988) |
| "RHT with trisekvens in combination with beta-blocker in long-term use potentiates the effect on systolic AP and reduced hypertrophy of the left ventricle." | 2.70 | [Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects]. ( Britov, AN; Bystrova, MM; Eliseeva, NA; Gorbunov, VM; Lebedev, AV; Slasten, OP; Smetnik, VP, 2001) |
| "Betaxolol has been proven to be a safe and effective antihypertensive agent, and was recently approved for clinical use in the United States for this indication." | 2.67 | Betaxolol: a new long-acting beta 1-selective adrenergic blocker. ( Behrman, D; Frishman, WH; Lazar, EJ; Tepper, D, 1990) |
| "Propranolol was associated with a documented increase in the degree of bronchial obstruction." | 2.66 | [Effect of different beta-receptor blockers on the respiratory function of patients with chronic obstructive pulmonary disease and arterial hypertension]. ( Dorow, P, 1987) |
| "Betaxolol is a cardioselective beta-blocker, which has a bioavailability of 90% and a T 1/2 of 20 h." | 2.65 | Comparison of two doses of betaxolol and placebo in hypertension: a randomized, double-blind cross-over trial. ( Palminteri, R; Salonen, JT, 1982) |
| "Betaxolol is a relatively cardioselective beta-adrenoceptor blocking drug, with no partial agonist (intrinsic sympathomimetic) activity and weak membrane-stabilising (local anaesthetic) activity." | 2.37 | Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. ( Beresford, R; Heel, RC, 1986) |
| "Betaxolol is a selective antagonist of beta(1)-adrenergic receptors." | 1.34 | Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. ( Brovkin, AN; Manchaeva, BB; Minushkina, LO; Nikitin, AG; Nosikov, VV; Savel'eva, EG; Sidorenko, BA; Zateyshchikov, DA; Zateyshchikova, AA, 2007) |
| " Among the 8 subjects in whom doxazosin dosage was increased to the maximum of 4 mg, the mean blood pressure achieved at 4 mg did not differ from that achieved at 2 mg (136/87 v 136/88 mm Hg)." | 1.31 | Low-dose alpha/beta blockade in the treatment of essential hypertension. ( Gerber, LM; Mann, SJ, 2001) |
| "Betaxolol is a highly selective beta 1-adrenoceptor antagonist without intrinsic sympathomimetic activity." | 1.28 | [Antihypertensive effect of betaxolol, a cardioselective beta-adrenoceptor antagonist, in experimental hypertensive rats]. ( Bessho, H; Narimatsu, A; Suzuki, J; Tobe, A, 1990) |
| "Treatment with betaxolol apparently inhibited the incidence of hypertensive lesions such as cardiac fibrosis, mesenteric vasculitis, proliferative and/or necrotic vasculitis and glomeruli showing collapse or vasculitis in the kidneys." | 1.28 | [Antihypertensive effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, in stroke-prone spontaneously hypertensive rats (SHRSP)]. ( Fujimoto, M; Itoh, M; Niwa, M; Ozaki, M; Sekine, I; Uchida, S; Yamashita, K, 1990) |
| "Betaxolol is a new beta-blocker that has been reported to have beta 1-selectivity, and it is devoid of both membrane stabilizing action and intrinsic sympathomimetic action." | 1.28 | Regional hemodynamic effects of betaxolol, a new selective beta 1-blocker, and atenolol in conscious spontaneously hypertensive rats. ( Abe, Y; Aki, Y; Fujisawa, Y; He, H; Horiuchi, K; Iwao, H; Kiyomoto, H; Nishiyama, A; Shoji, T; Tamaki, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (28.57) | 18.7374 |
| 1990's | 30 (47.62) | 18.2507 |
| 2000's | 13 (20.63) | 29.6817 |
| 2010's | 2 (3.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hering, D | 1 |
| Kucharska, W | 1 |
| Chrostowska, M | 1 |
| Narkiewicz, K | 1 |
| Latfullin, IA | 1 |
| Ishmurzin, GP | 1 |
| Gaĭfullina, RF | 1 |
| Akhmerova, RI | 1 |
| Kim, ZF | 1 |
| Podol'skaia, AA | 1 |
| Miki, A | 1 |
| Tanaka, Y | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Kobayashi, N | 2 |
| Yoshida, K | 1 |
| Mita, S | 2 |
| Honda, T | 2 |
| Hara, K | 1 |
| Nakano, S | 2 |
| Tsubokou, Y | 2 |
| Matsuoka, H | 2 |
| Dabrowski, R | 1 |
| Wozniak, J | 1 |
| Kowalik, I | 1 |
| Szwed, H | 1 |
| Belousov, IuB | 1 |
| Egorova, NA | 1 |
| Sidorenko, BA | 3 |
| Ivleva, AIu | 1 |
| Ageev, FT | 2 |
| Oleĭnikov, VE | 1 |
| Soucek, M | 3 |
| Rihacek, I | 3 |
| Frana, P | 2 |
| Orlova, IaA | 1 |
| Kulev, BD | 1 |
| Tsybul'skaia, TV | 1 |
| Korobova, EI | 1 |
| Baldina, ON | 1 |
| Zateyshchikov, DA | 1 |
| Minushkina, LO | 2 |
| Brovkin, AN | 1 |
| Savel'eva, EG | 2 |
| Zateyshchikova, AA | 1 |
| Manchaeva, BB | 1 |
| Nikitin, AG | 2 |
| Nosikov, VV | 2 |
| Zateĭshchikova, AA | 1 |
| Zateĭshchikov, DA | 1 |
| Mankhaeva, BB | 1 |
| Kochkina, MS | 1 |
| Brovkin, AV | 1 |
| Takase, B | 1 |
| Takeishi, Y | 1 |
| Hirai, T | 1 |
| Lee, JD | 1 |
| Uzui, H | 1 |
| Senda, S | 1 |
| Miwa, K | 1 |
| Hiraoka, Y | 1 |
| Kinugawa, T | 1 |
| Hosokawa, R | 1 |
| Fujita, M | 1 |
| Salonen, JT | 1 |
| Palminteri, R | 1 |
| Carré, AG | 1 |
| Bertrand, ME | 1 |
| Libersa, CC | 1 |
| Demerville, JC | 1 |
| Lekieffre, JP | 1 |
| Julínek, J | 1 |
| Stejfa, M | 1 |
| Fenichel, RR | 1 |
| Lipicky, RJ | 1 |
| Saku, K | 1 |
| Zhang, B | 1 |
| Okamoto, T | 1 |
| Takeda, Y | 1 |
| Liu, K | 1 |
| Jimi, S | 1 |
| Arakawa, K | 1 |
| Christ, M | 1 |
| Rauen, P | 1 |
| Klauss, V | 1 |
| Krüger, T | 1 |
| Frey, A | 1 |
| Theisen, K | 1 |
| Wehling, M | 1 |
| Hardee, JT | 1 |
| Roldan, CA | 1 |
| Du Clos, TW | 1 |
| Keltai, M | 1 |
| Matos, L | 1 |
| Ofner, P | 1 |
| Moiseev, VS | 1 |
| Moiseev, SV | 1 |
| Lazebnik, LB | 1 |
| Komissarenko, IA | 1 |
| Guseĭnzade, M | 1 |
| Shakurova, MIu | 1 |
| Karazhanova, LK | 1 |
| Abdrakhmanov, AS | 1 |
| Bystrova, MM | 2 |
| Britov, AN | 2 |
| Gorbunov, VM | 2 |
| Lebedev, AV | 2 |
| Eliseeva, NA | 2 |
| Metel'skaia, VA | 1 |
| Mann, SJ | 1 |
| Gerber, LM | 1 |
| Smetnik, VP | 1 |
| Slasten, OP | 1 |
| Mori, Y | 1 |
| Kobayashi, T | 1 |
| van Os, JS | 1 |
| van Brummelen, P | 1 |
| Woittiez, AJ | 1 |
| Shoji, T | 1 |
| Aki, Y | 1 |
| Horiuchi, K | 1 |
| Tamaki, T | 1 |
| He, H | 1 |
| Nishiyama, A | 1 |
| Kiyomoto, H | 1 |
| Fujisawa, Y | 1 |
| Iwao, H | 1 |
| Abe, Y | 1 |
| Williams, RL | 1 |
| Goyle, KK | 1 |
| Herman, TS | 1 |
| Rofman, BA | 1 |
| Ruoff, GE | 1 |
| Hogan, LB | 2 |
| Hollenbeck, M | 3 |
| Plum, J | 3 |
| Heering, P | 3 |
| Kutkuhn, B | 1 |
| Grabensee, B | 3 |
| Ameling, EH | 1 |
| de Korte, DF | 1 |
| Man in 't Veld, A | 1 |
| Chrysant, SG | 2 |
| Chrysant, C | 2 |
| Sadeghi, M | 1 |
| Berlin, L | 1 |
| Esunge, PM | 1 |
| Marsalek, P | 1 |
| Boutroy, MJ | 3 |
| Morselli, PL | 3 |
| Bianchetti, G | 3 |
| Boutroy, JL | 3 |
| Pépin, L | 1 |
| Zipfel, A | 3 |
| Bessho, H | 1 |
| Suzuki, J | 1 |
| Narimatsu, A | 1 |
| Tobe, A | 1 |
| Uchida, S | 1 |
| Itoh, M | 1 |
| Fujimoto, M | 1 |
| Yamashita, K | 1 |
| Niwa, M | 1 |
| Sekine, I | 1 |
| Ozaki, M | 1 |
| Frishman, WH | 1 |
| Tepper, D | 1 |
| Lazar, EJ | 1 |
| Behrman, D | 1 |
| Waeber, B | 2 |
| Burnier, M | 1 |
| Nussberger, J | 2 |
| Brunner, HR | 2 |
| Vert, P | 1 |
| Bal, IS | 1 |
| Trus, J | 1 |
| Hitchcock, A | 1 |
| Reams, GP | 3 |
| Bauer, JH | 3 |
| Cramer, P | 1 |
| Régnier, F | 1 |
| Burris, JF | 2 |
| Davidov, ME | 2 |
| Jenkins, P | 1 |
| Rofman, B | 1 |
| Ginsberg, D | 1 |
| Rosenbaum, R | 1 |
| Ryan, JR | 1 |
| Jain, AK | 1 |
| Mroczek, WJ | 2 |
| Djian, J | 1 |
| Beresford, R | 1 |
| Heel, RC | 1 |
| Lau, A | 2 |
| Herpin, D | 1 |
| Boutaud, P | 1 |
| Ciber, MA | 1 |
| Amiel, A | 1 |
| Demange, J | 1 |
| Citron, DC | 1 |
| Barker, AH | 1 |
| McDonald, RH | 1 |
| Dorow, P | 1 |
| Glazer, N | 1 |
| Wollam, G | 1 |
| Zager, PG | 1 |
| Cangiano, J | 1 |
| Steiner, A | 1 |
| Hany, S | 1 |
| Bättig, B | 1 |
| Jenni, R | 1 |
| Troesch, M | 1 |
| Willimann, P | 1 |
| Graf, A | 1 |
| Leutenegger, F | 1 |
| Angehrn, V | 1 |
| Beck, G | 2 |
| Waeber, G | 1 |
| Bidiville, J | 1 |
| Madonna, O | 1 |
| Labeeuw, M | 1 |
| Pozet, N | 1 |
| Aissa, AH | 1 |
| Zech, P | 1 |
| Frisk-Holmberg, M | 1 |
| Ström, G | 1 |
2 reviews available for betaxolol and Blood Pressure, High
| Article | Year |
|---|---|
[Betaxolol (lokren) in arterial hypertension].
Topics: Antihypertensive Agents; Betaxolol; Hemodynamics; Humans; Hypertension; Time Factors | 1998 |
Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Antihypertensive Agents; Betaxolol; Chemical Phenomena; | 1986 |
28 trials available for betaxolol and Blood Pressure, High
| Article | Year |
|---|---|
Working women are better responders to beta-blocker monotherapy of mild hypertension than men.
Topics: Adrenergic beta-Antagonists; Betaxolol; Female; Humans; Hypertension; Male; Middle Aged; Sex Factors | 2004 |
[Confirmation of safety and therapeutic effect of betaxolol in the treatment of mild and moderate hypertension in general medical practice].
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Female; Humans; Hypertension; Male; Middle Aged; Prim | 2005 |
A comparison of the trough-to-peak ratio of cardio-selective beta-blockers in patients with newly diagnosed hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2006 |
Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Betaxolol; Blood Pressure; Calc | 2008 |
Comparison of two doses of betaxolol and placebo in hypertension: a randomized, double-blind cross-over trial.
Topics: Betaxolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; H | 1982 |
Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Apolipoproteins; Betaxolol; Calcium Channel Blockers; Drug | 1996 |
Spontaneous changes of heart rate, blood pressure, and ischemia-type ST-segment depressions in patients with hypertension without significant coronary artery disease: beneficial effects of beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Blood Pressure; Blood Pressure Monitoring, Ambu | 1996 |
[Effect of betaxolol on blood pressure and heart rate in mild to moderate hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Betaxolol; Female; Humans; Hypertension; Male; Middle Aged; Se | 1997 |
[Optimization of hypotensive therapy in hypertensive patients with new beta-1 selective long-acting adrenoblocker].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Betaxolol; Blood Pressure; Dela | 1998 |
[Betaxolol treatment of hypertension in postmenopausal women].
Topics: Adrenergic beta-Antagonists; Betaxolol; Blood Glucose; Blood Pressure; Body Mass Index; Female; Foll | 1999 |
[Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Climacteric; Drug Combinations; Dru | 2001 |
Betaxolol in obese hypertensive patients. Long-term effects on blood pressure and serum lipids.
Topics: Betaxolol; Blood Pressure; Cholesterol; Drug Evaluation; Female; Humans; Hypertension; Male; Middle | 1992 |
Dose-dependent effects of betaxolol in hypertension: a double-blind, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Dose-Response Relationship, Drug; Double- | 1992 |
Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol.
Topics: Adult; Betaxolol; Blood Pressure; Cognition; Double-Blind Method; Female; Heart Rate; Humans; Hypert | 1991 |
Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension.
Topics: Betaxolol; Cardiomegaly; Drug Therapy, Combination; Edema; Furosemide; Humans; Hypertension; Male; M | 1991 |
Patient compliance and the evaluation of drug trials for hypertension in rural Africa.
Topics: Adult; Aged; Betaxolol; Blood Pressure; Cameroon; Drug Costs; Female; Heart Rate; Humans; Hypertensi | 1991 |
Betaxolol for hypertension.
Topics: Adrenergic beta-Antagonists; Betaxolol; Double-Blind Method; Humans; Hypertension; Multicenter Studi | 1990 |
Betaxolol: a new long-acting beta 1-selective adrenergic blocker.
Topics: Adult; Arrhythmias, Cardiac; Betaxolol; Biological Availability; Blood Pressure; Clinical Trials as | 1990 |
Trials using a crossover design and ambulatory blood pressure recordings to determine the efficacy of antihypertensive agents in individual patients.
Topics: Ambulatory Care; Betaxolol; Blood Pressure; Delayed-Action Preparations; Drug Administration Schedul | 1990 |
Treatment of severe hypertension with atenolol and betaxolol with once-daily regimens. Hemodynamic aspects.
Topics: Adrenergic beta-Antagonists; Atenolol; Betaxolol; Double-Blind Method; Drug Administration Schedule; | 1989 |
Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination.
Topics: Betaxolol; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, Combination; Female; H | 1989 |
[Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Betaxolol; Female; Humans; Hypertension; Male; Propano | 1987 |
Comparison of the antihypertensive effects of betaxolol to atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Betaxolol; Blood Pressure; Bradycardia; Clinical Trials as To | 1988 |
[Effect of different beta-receptor blockers on the respiratory function of patients with chronic obstructive pulmonary disease and arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Blood Pressure; Female; Heart Rate; Humans; Hypertens | 1987 |
Comparison of betaxolol, a new beta 1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Clinical Trials as Topic; Female; Heart Rate; H | 1988 |
[Betaxolol versus nifedipine in the treatment of essential hypertension].
Topics: Adrenergic beta-Antagonists; Betaxolol; Blood Pressure; Echocardiography; Female; Heart Rate; Humans | 1988 |
Comparison of betaxolol with verapamil in hypertensive patients: discrepancy between office and ambulatory blood pressures.
Topics: Adult; Aged; Betaxolol; Blood Pressure; Blood Pressure Determination; Clinical Trials as Topic; Fema | 1988 |
A comparison of betaxolol and nadolol on renal function in essential hypertension.
Topics: Betaxolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Humans; Hyper | 1987 |
33 other studies available for betaxolol and Blood Pressure, High
| Article | Year |
|---|---|
Age-dependent sympathetic neural responses to ß
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Age Factors; Betaxolol; Blood Pressure; Heart Rate; H | 2018 |
[Beta-adrenoblockers for the correction of arterial hypertension in postmenopausal women].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Carbazoles; Carvedilol; Female; Hum | 2010 |
Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on beta-receptor occupancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Asthma; Betaxolol; Drug Therapy, Combinatio | 2003 |
Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats.
Topics: Animals; Antihypertensive Agents; Betaxolol; Collagen Type I; Hypertension; Intercellular Adhesion M | 2004 |
[Clinical and vascular effects of betaxolol in patients with arterial hypertension].
Topics: Adrenergic beta-Antagonists; Betaxolol; Blood Flow Velocity; Blood Pressure; Female; Follow-Up Studi | 2006 |
[The smoothness index of betaxolol hydrochloride in patients with newly diagnosed hypertension].
Topics: Antihypertensive Agents; Betaxolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; H | 2007 |
Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Antihypertensive Agents; Betaxolol; Blood Pressure; Cytochro | 2007 |
[Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension].
Topics: Adrenergic beta-Antagonists; Alleles; Betaxolol; Blood Pressure; Cytochrome P-450 CYP2D6; DNA; Elect | 2008 |
[Acute hemodynamic effects of betaxolol in uncomplicated arterial hypertension in young persons].
Topics: Adolescent; Adult; Betaxolol; Blood Pressure; Cardiac Output; Female; Heart Rate; Humans; Hypertensi | 1982 |
[Betaxolol hydrochloride in the treatment of mild and medium hypertension--long-term effects].
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Blood Pressure; Female; Humans; Hypertension; Male; M | 1995 |
Combination products as first-line pharmacotherapy.
Topics: Betaxolol; Bisoprolol; Chlorthalidone; Drug Approval; Drug Combinations; Humans; Hydrochlorothiazide | 1994 |
Betaxolol and drug-induced lupus complicated by pericarditis and large pericardial effusion.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Disease-Free S | 1997 |
[Advantageous risk-benefit ratio of betaxolol].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Humans; Hypertension; Risk Assessme | 1997 |
[The beta blocker Betaxolol--a significant alternative in hypertension therapy].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Humans; Hypertension | 1998 |
[Pharmacodynamic effects of lokren (betaxolol) in 3 month treatment of blood hypertension in elderly patients].
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Blood Pressure; Female; Follow-Up Studies; Humans; Hyp | 1998 |
Low-dose alpha/beta blockade in the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Angiotensin- | 2001 |
Betaxolol inhibits extracellular signal-regulated kinase and P70S6 kinase activities and gene expressions of platelet-derived growth factor A-chain and transforming growth factor-beta1 in Dahl salt-sensitive hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Body Weight; Gene Expression; Hemodynamics; Hyperte | 2002 |
Regional hemodynamic effects of betaxolol, a new selective beta 1-blocker, and atenolol in conscious spontaneously hypertensive rats.
Topics: Animals; Atenolol; Betaxolol; Blood Pressure; Cardiac Output; Heart Rate; Hypertension; Male; Micros | 1992 |
Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension.
Topics: Adolescent; Adult; Aldosterone; Atrial Natriuretic Factor; Betaxolol; Exercise Test; Female; Furosem | 1991 |
[Constant beta blockade around the clock. Drug study in general practice conditions].
Topics: Adult; Betaxolol; Blood Pressure; Drug Administration Schedule; Female; Heart Rate; Humans; Hyperten | 1991 |
Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Betaxolol; Blood Pressure; Body Weight; Electrocardi | 1990 |
[Antihypertensive effect of betaxolol, a cardioselective beta-adrenoceptor antagonist, in experimental hypertensive rats].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Betaxolol; Blood Pressure; Dose-Response | 1990 |
[Antihypertensive effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, in stroke-prone spontaneously hypertensive rats (SHRSP)].
Topics: Adrenergic beta-Agonists; Animals; Betaxolol; Blood Pressure; Brain; Heart Rate; Hypertension; Kidne | 1990 |
[Effect of betaxolol on atrial natriuretic peptide regulation in patients with essential hypertension].
Topics: Adolescent; Adult; Atrial Natriuretic Factor; Betaxolol; Blood Pressure; Blood Volume; Female; Glome | 1990 |
[Effect of a beta 1-receptor blocker on the plasma level of atrial natriuretic peptide in patients with essential hypertension in the exercise test].
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Betaxolol; Blood Pressure; Cyclic GMP; Exercise Test; | 1990 |
Oral betaxolol approved for once-daily therapy of hypertension.
Topics: Betaxolol; Humans; Hypertension | 1990 |
Placental transfer and perinatal pharmacokinetics of betaxolol.
Topics: Adult; Amniotic Fluid; Betaxolol; Chromatography, High Pressure Liquid; Female; Fetal Blood; Half-Li | 1990 |
The effect of triple drug therapy on renal function in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Antihypertensive Agents; Atenolol; Betaxolol; Blood | 1989 |
[Open trial of betaxolol in the treatment of arterial hypertension in pregnancy, pilot study].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Betaxolol; Drug Evaluation; Female; Fetus; Humans; H | 1989 |
Clinical evaluation of betaxolol (Kerlone) as a once-daily treatment for hypertension in 4685 patients.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Drug Administration Schedule; Drug | 1985 |
The acute and chronic effects of betaxolol on blood pressure, renin-aldosterone, and renal function in essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Betaxolol; Blood Pressure; Humans; Hypertension; Kid | 1987 |
Influence of treatment by betaxolol on the renal response to postural changes in moderate hypertension.
Topics: Adult; Betaxolol; Humans; Hypertension; Kidney; Kidney Function Tests; Posture; Propanolamines; Reni | 1988 |
Exercise during therapeutic beta-blockade: a two-year study in hypertensive patients.
Topics: Adult; Betaxolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Physi | 1986 |